296 related articles for article (PubMed ID: 32067841)
1. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
2. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
4. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
5. HPA-1, 3, 5 genotyping to establish a typed platelet donor panel.
Verran J; Grey D; Bennett J; Lown JA; Erber WN
Pathology; 2000 May; 32(2):89-93. PubMed ID: 10840826
[TBL] [Abstract][Full Text] [Related]
6. How do I … manage the platelet transfusion-refractory patient?
Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD
Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
[TBL] [Abstract][Full Text] [Related]
7. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
Sintnicolaas K; Löwenberg B
Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
Heal JM; Blumberg N; Masel D
Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
[TBL] [Abstract][Full Text] [Related]
9. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
10. HLA-Mediated Platelet Refractoriness.
Schmidt AE; Refaai MA; Coppage M
Am J Clin Pathol; 2019 Mar; 151(4):353-363. PubMed ID: 30285067
[TBL] [Abstract][Full Text] [Related]
11. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
12. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test.
Skogen B; Christiansen D; Husebekk A
Transfusion; 1995 Oct; 35(10):832-6. PubMed ID: 7570913
[TBL] [Abstract][Full Text] [Related]
14. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
15. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.
Jackman RP; Deng X; Bolgiano D; Lebedeva M; Heitman JW; Busch MP; Slichter SJ; Norris PJ
Blood; 2013 Apr; 121(16):3261-6; quiz 3299. PubMed ID: 23393051
[TBL] [Abstract][Full Text] [Related]
16. Platelet transfusion refractoriness.
Hod E; Schwartz J
Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
[TBL] [Abstract][Full Text] [Related]
17. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Pappalardo PA; Secord AR; Quitevis P; Haimowitz MD; Goldfinger D
Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
[TBL] [Abstract][Full Text] [Related]
18. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
[TBL] [Abstract][Full Text] [Related]
19. Platelet transfusions: the problem of refractoriness.
Murphy MF; Waters AH
Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
[TBL] [Abstract][Full Text] [Related]
20. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
